Details of Drug-Drug Interaction
| Drug General Information (ID: DDIWAP5D9E) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Terazosin | Drug Info | Licorice | Drug Info | |||||
| Drug Type | Small molecule | Natural product | |||||||
| Therapeutic Class | Antineoplastics | Herbal Products | |||||||
| Structure | |||||||||
| Mechanism of Terazosin-Licorice Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of antihypertensive agents Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Terazosin | Licorice | |||||||
| Mechanism |
Antihypertensive agent Alpha-1 adrenergic receptor Antagonist |
Hypertensive effects Mineralocorticoid and renin-suppressing effects |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Adrenergic receptor alpha-1 | Structure Sequence | |||||||
| Protein Family | G-protein coupled receptor 1 family | ||||||||
| Protein Function |
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Click to Show/Hide
|
||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products. Even relatively moderate doses of licorice may be problematic in susceptible patients when ingested regularly for prolonged periods. | ||||||||